Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $6.05M (cash outflow) rose 13.5% year over year, behind the +46.8% change in trailing-twelve-month net income. Sequentially, it fell 17.3% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$22.82M (-13.7%) for the fiscal year ending Dec 2026, a slowdown from the +39.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.05M-17.3% QoQ
- Last fiscal yearDec 2025
- -$26.44M+39.2% YoY
- LTMMar 2026
- -$29.59M+46.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.5% | -3.1% | -16.6 pp |
| 1 year | +39.2% | -13.7% | -52.9 pp |
| 3-year CAGR | +11.5% | +3.9% | -7.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (26.44M) USD
- Year-over-year change
- -39.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.44M) | -39.2% |
| FY2024 | 2024-12-31 | (19M) | +14.6% |
| FY2023 | 2023-12-31 | (22.26M) | -16.6% |
| FY2022 | 2022-12-31 | (19.09M) | -48.1% |
| FY2021 | 2021-12-31 | (12.89M) | — |
Net Income vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 net income of $29.59M is the smallest of the 11 companies compared; the peer median is $69.27M.
- Its year-over-year change of +46.8% is the 4th highest of 11, against a peer median of +24.8%.
- Over three fiscal years its annual growth of +11.5% compares with a peer median of +20.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $243.25M | -26.6% | +24.1% | 112.0% | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $114.48M | +47.3% | +21.7% | 529.7% | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $68.17M | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| LTM Mar 2026 | $35.71M | -24.3% | -0.3% | 7142.0% | |
| LTM Mar 2026 | $34.98M | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $29.59M | +46.8% | +11.5% | — | |
| Peer median (excluding NVCT) | $69.27M | +24.8% | +20.5% | 251.6% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.